首站-论文投稿智能助手
典型文献
Clinical experience of liver transplantation in the treatment of peliosis hepatis
文献摘要:
To the Editor: Peliosis hepatis (PH) is an uncommon benign vascular disorder characterized by widespread blood-filled cysts in the liver. This dis- ease was first described by Wagner in 1861, and because the liver lesions were generally red or blue-purple, it was first named PH by Schoenlack in 1916 [1] . The etiology of PH is not completely clear now, which is mainly related to drug factors, immune fac- tors, and infections. The diagnosis of PH is difficult because of the lack of specific clinical manifestations and imaging features. Patho- logical biopsy represents the gold standard in diagnosis of PH [2] . The treatment of PH varies from person to person and no consen- sus has been reached, including the removal of pathogenic factors, hepatic artery embolization, hepatectomy, etc. [3 , 4] . Liver trans- plantation (LT) may be the best treatment for PH with fatal com- plications [5 , 6] . This study described a rare case of recurrence of PH after LT.
文献关键词:
作者姓名:
Yang Zhao;Yu Liu;Lin Zhou;Xin-Xue Zhang;Ping Li;Qiang He
作者机构:
Department of Hepatobiliary Surgery,Beijing Chaoyang Hospital,Capital Medical University,No.8,Gongtinan Road,Chaoyang District,Beijing 100020,China
引用格式:
[1]Yang Zhao;Yu Liu;Lin Zhou;Xin-Xue Zhang;Ping Li;Qiang He-.Clinical experience of liver transplantation in the treatment of peliosis hepatis)[J].国际肝胆胰疾病杂志(英文版),2022(01):83-85
A类:
peliosis,hepatis, Peliosis,Schoenlack,Patho,consen
B类:
Clinical,experience,liver,transplantation,treatment,To,Editor,PH,uncommon,benign,vascular,disorder,characterized,by,widespread,blood,filled,cysts,This,ease,was,first,described,Wagner,because,lesions,were,generally,red,blue,purple,named,etiology,not,completely,clear,now,which,mainly,related,drug,factors,immune,infections,diagnosis,difficult,specific,clinical,manifestations,imaging,features,logical,biopsy,represents,gold,standard,varies,from,person,sus,has,been,reached,including,removal,pathogenic,hepatic,artery,embolization,hepatectomy,etc,Liver,LT,may,best,fatal,plications,study,rare,case,recurrence,after
AB值:
0.567431
相似文献
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
Prognostic nomogram incorporating radiological features for predicting overall survival in patients with AIDS-related non-Hodgkin lymphoma
Li Xueqin;Pan Ziang;Wang Xing;Hu Tianli;Ye Wen;Jiang Dongmei;Shen Wen;Liu Jinxin;Shi Yuxin;Xia Shuang;Li Hongjun-Radiological Department, Beijing You'an Hospital Affiliated of Capital Medical University, Beijing 100069, China;Neurological Department, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;Radiological Department, The Eighth People's Hospital of Guangzhou, Guangzhou, Guangdong 510060, China;Radiological Department, Shanghai Public Health Clinical Center, Affiliated of Fudan University, Shanghai 201058, China;Radiation Department, Tianjin First Central Hospital, Tianjin 300170, China;Radiological Department, Tianjin First Central Hospital, Tianjin 300192, China
Dynamic changes of renal cortical blood perfusion before and after percutaneous transluminal renal artery stenting in patients with severe atherosclerotic renal artery stenosis
Ma Na;Li Yan;Wang Siyu;Li Mengpu;Li Yongjun;Ai Hu;Zhu Hui;Wang Yang;Guo Fajin;Ren Junhong-Department of Sonography, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Vascular Surgery, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Cardiology, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Nuclear Medicine, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing 100730, China;Department of Medical Research & Biometrics Center, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing 100037, China
Prevalence, risk factors, and survival associated with pulmonary hypertension and heart failure among patients with underlying coronary artery disease: a national prospective, multicenter registry study in China
Huang Li;Pang Lingpin;Gu Qing;Yang Tao;Li Wen;Quan Ruilin;Su Weiqing;Wu Weifeng;Tang Fangming;Zhu Xiulong;Shen Jieyan;Sun Jingzhi;Shan Guangliang;Xiong Changming;Huang Shian;He Jianguo-Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China;Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 510180, China;Center of Pulmonary Vascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100007, China;Department of Cardiology, Lianjiang People’s Hospital, Lianjiang, Guangdong 524499, China;Department of Cardiology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China;Department of Cardiology, Nongken Central Hospital of Guangdong Province, Zhanjiang, Guangdong 529632, China;Department of Cardiology, People’s Hospital of Gaozhou, Gaozhou, Guangdong 525232, China;Department of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Cardiology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272007, China;Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100006, China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。